Radioactive antibody combo aims to beat back tough hodgkin lymphoma

NCT ID NCT04871607

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new approach for people with Hodgkin lymphoma that has not responded to treatment or has come back. It combines a radioactive antibody (yttrium-90 labeled anti-CD25) with standard BEAM chemotherapy before a stem cell transplant. The goal is to see if this combination can improve how long people stay cancer-free. The study plans to enroll 33 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Yttrium-90 labeled anti-CD25 monoclonal antibody (basiliximab) combined with BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan)
What this could lead to: If successful, this could improve the chance of long-term remission for people with Hodgkin lymphoma that has not responded to or returned after standard treatment.
What could go wrong: This is a small, early-phase trial (33 people) with no control group, so results may not apply broadly. The treatment includes high-dose chemo and radiation, which can cause serious side effects like infections and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT HODGKIN LYMPHOMA REFRACTORY HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.